Jennifer Wallet

778 total citations
27 papers, 329 citations indexed

About

Jennifer Wallet is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Jennifer Wallet has authored 27 papers receiving a total of 329 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Pulmonary and Respiratory Medicine, 16 papers in Oncology and 7 papers in Pathology and Forensic Medicine. Recurrent topics in Jennifer Wallet's work include Sarcoma Diagnosis and Treatment (12 papers), Vascular Tumors and Angiosarcomas (7 papers) and Lymphoma Diagnosis and Treatment (5 papers). Jennifer Wallet is often cited by papers focused on Sarcoma Diagnosis and Treatment (12 papers), Vascular Tumors and Angiosarcomas (7 papers) and Lymphoma Diagnosis and Treatment (5 papers). Jennifer Wallet collaborates with scholars based in France, Austria and Switzerland. Jennifer Wallet's co-authors include Marie‐Cécile Le Deley, Laurent Mineur, Andrew Kramar, Émilie Le Rhun, Christelle de la Fouchardière, Bernard Paule, Pascal Burtin, Michael Weller, Jacques Bonneterre and Louis-Marie Dourthe and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Annals of Oncology.

In The Last Decade

Jennifer Wallet

24 papers receiving 327 citations

Peers

Countries citing papers authored by Jennifer Wallet

Since Specialization

Citations

This map shows the geographic impact of Jennifer Wallet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jennifer Wallet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jennifer Wallet more than expected).

Fields of papers citing papers by Jennifer Wallet

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jennifer Wallet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jennifer Wallet. The network helps show where Jennifer Wallet may publish in the future.

Co-authorship network of co-authors of Jennifer Wallet

This figure shows the co-authorship network connecting the top 25 collaborators of Jennifer Wallet. A scholar is included among the top collaborators of Jennifer Wallet based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jennifer Wallet. Jennifer Wallet is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Regorafenib as maintenance therapy after first-line doxorubicin-based chemotherapy in advanced non-adipocytic soft tissue sarcomas patients: a double-blind randomised trial 2025 ·Annals of Oncology ·Nicolas Penel, Antoîne Italiano, Jennifer Wallet, L. Chaigneau, (unknown), Nelly Firmin, Sarah Watson, (unknown), Emmanuelle Bompas, François Bertucci, Mehdi Brahmi, Clémence Henon, Angélique Brunot, Mariella Spalato Ceruso, (unknown), (unknown), Thomas Ryckewaert, Marie‐Cécile Le Deley, Christophe Perrin, Jean‐Yves Blay	0
2	1718O EREMISS trial: A double-blind placebo (PBO)-controlled randomised trial assessing efficacy/safety of regorafenib (REGO) as maintenance therapy after 1st line doxorubicin-based chemotherapy in advanced soft-tissue sarcoma (ASTS) patients (pts) 2024 ·Annals of Oncology ·(unknown), (unknown), Jennifer Wallet, L. Chaigneau, (unknown), Nelly Firmin, Sarah Watson, Thomas Valentin, Emmanuelle Bompas, François Bertucci, (unknown), A. Le Cesne, Angélique Brunot, Mariella Spalato Ceruso, (unknown), (unknown), S. Taïeb, M. Le Deley, Christophe Perrin, Jean‐Yves Blay	1
3	IMRT in the treatment of locally advanced or inoperable NSCLC in the pre-durvalumab era: clinical outcomes and pattern of relapses, experience from the Oscar Lambret Center 2023 ·Frontiers in Oncology ·(unknown), Jennifer Wallet, (unknown), (unknown), T. Lacornerie, Dominique Pasquier, Éric Lartigau, (unknown)	1
4	Incidence and characteristics of chronic postsurgical pain at 6 months after total mastectomy under pectoserratus and interpectoral plane block combined with general anesthesia: a prospective cohort study 2023 ·Regional Anesthesia & Pain Medicine ·(unknown), Jennifer Wallet, (unknown), (unknown), (unknown), (unknown), (unknown), Marie‐Cécile Le Deley, (unknown)	2
5	Activity of regorafenib in patients with non-adipocytic soft tissue sarcoma (NASTS): Evaluation of heterogeneity of treatment effect on the updated analysis of pooled cohorts. 2022 ·Journal of Clinical Oncology ·Marie‐Cécile Le Deley, Jean‐Yves Blay, Jennifer Wallet, François Bertucci, Emmanuelle Bompas, Thomas Brodowicz, L. Chaigneau, Christine Chevreau, (unknown), Antoîne Italiano, (unknown), Olivier Mir, Sophie Piperno‐Neumann, (unknown), Axel Le Cesne, Nicolas Penel	4
6	Salvage Radiotherapy for Macroscopic Local Recurrence Following Radical Prostatectomy 2021 ·Frontiers in Oncology ·(unknown), (unknown), B. Bataille, T. Lacornerie, Jennifer Wallet, X. Mirabel, Éric Lartigau, Dominique Pasquier	6
7	Assessing Prognostic and Predictive Biomarkers of Regorafenib Response in Patients with Advanced Soft Tissue Sarcoma: REGOSARC Study 2020 ·Cancers ·Thomas Brodowicz, Bernadette Liegl‐Atzwanger, Nicolas Penel, Olivier Mir, Jean‐Yves Blay, Karl Kashofer, Axel Le Cesne, (unknown), Jennifer Wallet, Rainer Hamacher, Marie‐Cécile Le Deley	8
8	A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib 2020 ·European Journal of Cancer ·Nicolas Penel, Olivier Mir, Jennifer Wallet, Isabelle Ray‐Coquard, Axel Le Cesne, Antoîne Italiano, Sébastien Salas, Corinne Delcambre, Emmanuelle Bompas, François Bertucci, Esma Saâda-Bouzid, L. Chaigneau, Christine Chevreau, Thomas Brodowicz, (unknown), (unknown), (unknown), S. Taïeb, Marie‐Cécile Le Deley, Jean‐Yves Blay	9
9	Lomboaortic Lymphadenectomy in Gynecological Oncology: Laparotomy, Laparoscopy or Robot-Assisted Laparoscopy? 2020 ·Annals of Surgical Oncology ·Yohan Kerbage, (unknown), (unknown), Éric Lambaudie, Anne‐Sophie Bats, Thomas Hébert, Frédéric Goffin, Jennifer Wallet, Éric Leblanc, Delphine Hudry, Fabrice Narducci	6
10	Stereotactic Re-irradiation for Local Recurrence in the Prostatic Bed After Prostatectomy: Preliminary Results 2019 ·Frontiers in Oncology ·Jonathan Olivier, (unknown), Philippe Puech, T. Lacornerie, Arnauld Villers, Jennifer Wallet, Éric Lartigau, Dominique Pasquier	24
11	Intrathecal liposomal cytarabine plus systemic therapy versus systemic chemotherapy alone for newly diagnosed leptomeningeal metastasis from breast cancer 2019 ·Neuro-Oncology ·Émilie Le Rhun, Jennifer Wallet, Audrey Mailliez, Marie‐Cécile Le Deley, (unknown), Thomas Boulanger, Véronique Lorgis, Jérôme Barrière, Y Robin, Michael Weller, Jacques Bonneterre	69
12	EREMISS: Efficacy of regorafenib (REG) as maintenance therapy in non-adipocytic soft tissue sarcomas (STS) having received 1st-line doxorubicin-based chemotherapy (Doxo-CT) 2019 ·Annals of Oncology ·Nicolas Penel, Jean‐Yves Blay, Jennifer Wallet, Axel Le Cesne, Antoîne Italiano, Olivier Mir, S. Taïeb, (unknown), P. Desmet, (unknown), J Courtial, Marie‐Cécile Le Deley	0
13	OS10.4 Intrathecal liposomal cytarabine plus systemic therapy versus systemic chemotherapy alone for leptomeningeal metastasis from breast cancer - a randomized study. Final results 2019 ·Neuro-Oncology ·Émilie Le Rhun, Jennifer Wallet, Audrey Mailliez, Marie‐Cécile Le Deley, (unknown), Thomas Boulanger, Véronique Lorgis, Jérôme Barrière, Y Robin, Michael Weller, Jacques Bonneterre	1
14	Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcoma 2018 ·European Journal of Cancer ·Thomas Brodowicz, Olivier Mir, Jennifer Wallet, Antoîne Italiano, Jean‐Yves Blay, François Bertucci, Wolfgang Eisterer, Christine Chevreau, Sophie Piperno‐Neumann, Emmanuelle Bompas, Thomas Ryckewaert, (unknown), (unknown), Nicolas Penel, Axel Le Cesne, Marie‐Cécile Le Deley	15
15	Intra-CSF liposomal cytarabine plus systemic therapy as initial treatment of breast cancer leptomeningeal metastasis: A randomised, open-label trial 2018 ·Annals of Oncology ·Émilie Le Rhun, Audrey Mailliez, Jennifer Wallet, (unknown), Thomas Boulanger, Isabelle Desmoulins, Jérôme Barrière, Michel Fabbro, Sophie Taillibert, Charles André, Marie‐Cécile Le Deley, Michael Weller, Jacques Bonneterre	4
16	The importance of jointly analyzing treatment administration and toxicity associated with targeted therapies: a case study of regorafenib in soft tissue sarcoma patients 2018 ·Annals of Oncology ·(unknown), Bastien Cabarrou, Jennifer Wallet, Thomas Brodowicz, H. Roché, Jean‐Marie Boher, Jean‐Pierre Delord, Nicolas Penel, Thomas Filleron	5
17	REGOSARC: Regorafenib versus placebo in doxorubicin‐refractory soft‐tissue sarcoma—A quality‐adjusted time without symptoms of progression or toxicity analysis 2017 ·Cancer ·Vincent Berry, (unknown), Emilie Bogart, Olivier Mir, Jean‐Yves Blay, Antoîne Italiano, François Bertucci, Christine Chevreau, (unknown), (unknown), Emmanuelle Tresch‐Bruneel, Jennifer Wallet, S. Taïeb, (unknown), Axel Le Cesne, Thomas Brodowicz, Nicolas Penel	36
18	Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program 2016 ·BMC Cancer ·Antoine Adenis, Christelle de la Fouchardière, Bernard Paule, Pascal Burtin, David Tougeron, Jennifer Wallet, Louis-Marie Dourthe, Pierre-Luc Etienne, Laurent Mineur, Stéphanie Clisant, Jean–Marc Phelip, Andrew Kramar, Thierry André	91
19	Activity of regorafenib (RE) in leiomyosarcomas (LMS) and other types of soft-tissue sarcomas (OTS): Results of a double-blind, randomized placebo (PL) controlled phase II trial. 2015 ·Journal of Clinical Oncology ·Olivier Mir, Thomas Brodowicz, Jennifer Wallet, Antoîne Italiano, Axel Le Cesne, Jean‐Yves Blay, Thomas Ryckewaert, François Bertucci, Sophie Piperno‐Neumann, Ferdinand Ploner, Maud Toulmonde, Julien Dômont, Esma Saâda, Corinne Delcambre, Nicolás Isambert, (unknown), S. Taïeb, (unknown), (unknown), Nicolas Penel	9
20	BMET-25RESULTS OF THE INTERIM SAFETY ANALYSIS OF THE DEPOSEIN TRIAL IN LEPTOMENINGEAL METASTASES FROM BREAST CANCER 2015 ·Neuro-Oncology ·Émilie Le Rhun, Fahed Zaïri, Thomas Boulanger, Jérôme Barrière, Michel Fabbro, Jennifer Wallet, J. Bonneterre, Sophie Taillibert	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact